Clinical Trial Update: Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study to evaluate the effect of food on dosing of AZD6244 HydSulfate (selumetinib) in patients with advanced solid malignancies, including melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• AZD6244 HydSulfate (selumetinib)

Snippet

Sponsor: AstraZeneca | Conditions: Melanoma, Malignant Melanoma | Phase 1 | Status: COMPLETED